A Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Cariprazine in Patients With Bipolar Depression
Phase of Trial: Phase II
Latest Information Update: 04 May 2018
At a glance
- Drugs Cariprazine (Primary)
- Indications Bipolar I disorders
- Focus Therapeutic Use
- Sponsors Forest Laboratories
- 03 Apr 2018 According to the Allergan media release, company plans to include data from this and other two pivotal trials (700267785 and 700267733) in the Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) in the second half of 2018.
- 06 Nov 2015 Results published online in the American Journal of Psychiatry.
- 20 May 2015 Results presented at the 168th Annual Meeting of the American Psychiatric Association.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History